top of page
The Sound of Evolution
Vandetanib
Mechanism of action:
Vandetanib is a multi-target tyrosine kinase inhibitor. Most medullary thyroid cancers carry activating mutations in the RET proto-oncogene, and vandetanib inhibits RET kinase autophosphorylation, thereby blocking downstream signaling pathways such as MAPK and PI3K/Akt and suppressing tumor cell proliferation and survival. Vandetanib also inhibits VEGFR-2, reducing tumor angiogenesis and diminishing the blood supply to the tumor.
Reference(s):
1. Bates D et al. (2003). ZD-6474. AstraZeneca. Curr Opin Investig Drugs.
2. Ton GN et al. (2013). Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm.
bottom of page